MedTrace Logo

A Study of DC-CIK to Treat Hepatocellular Carcinoma

NCT01821482 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2013-04-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of Dendritic and Cytokine-induced Killer Cells (DC-CIK) for hepatocellular carcinoma (HCC).

Conditions

  • Hepatocellular Carcinoma (HCC)

Interventions

BIOLOGICAL

Dendritic and Cytokine-induced Killer Cells

Sponsors & Collaborators

  • Guangxi Medical University

    lead OTHER

Principal Investigators

  • Hanfeng Liu · Guangxi Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2018-05-31
Completion
2018-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01821482 on ClinicalTrials.gov